Caribou Biosciences (CRBU) Enterprise Value (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Enterprise Value data on file, last reported at -$117.6 million in Q1 2026.

• Enterprise Value for Q1 2026 came in at -$117.6 million, up 43.58% year-over-year; the trailing twelve-month figure through Mar 2026 was -$117.6 million (up 43.58% YoY), and the FY2025 annual result was -$139.3 million, up 33.5% from the prior year.
• Enterprise Value rose to -$117.6 million in Q1 2026 per CRBU's latest filing, from -$139.3 million in the prior quarter.
• Over five years, Enterprise Value peaked at -$117.6 million in Q1 2026 and troughed at -$353.7 million in Q1 2022.
• A 5-year average of -$245.9 million and a median of -$247.7 million in 2022 frame the typical range for Enterprise Value.
• The sharpest annual moves came in 2022 and 2026: Enterprise Value tumbled 738865.22% in 2022, then surged 43.58% in 2026.
• A 5-year view of Enterprise Value shows it stood at -$247.7 million in 2022, then plunged by 32.77% to -$328.8 million in 2023, then jumped by 36.28% to -$209.5 million in 2024, then jumped by 33.5% to -$139.3 million in 2025, then grew by 15.58% to -$117.6 million in 2026.
• Business Quant data shows CRBU's Enterprise Value at -$117.6 million in Q1 2026, -$139.3 million in Q4 2025, and -$147.3 million in Q3 2025.